Drug Profile
GRC 39815
Alternative Names: GRC-39815; GRC39815-ALatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Anti-inflammatories
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in India (Inhalation)
- 10 Feb 2023 Phase-I clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
- 08 Feb 2022 GRC 39815 is still in preclinical phase for Chronic obstructive pulmonary disease in India